HCC

The initial pilot study of CTL019 in heavily pretreated CD19-positive hematologic malignancies demonstrated the feasibility of CAR T-cell therapy in patients with CLL. A presentation at the 2019 American Society of Gene & Cell Therapy Annual Meeting reported 2 cases of chemotherapy-resistant CLL, with ongoing follow- up at 8 years showing persistence of CAR-engineered T cells and sustained remission, as determined by flow cytometry and deep sequencing of immunoglobulin H rearrangements. 

The research around best radiation-based treatment options for patients with hepatocellular carcinoma are over 15 years old, but the standard of care for long-term management of the disease is still conventional chemoembolization, according to Emil I. Cohen, MD, assistant professor, Georgetown University Hospital.

In an interview with <em>Targeted Oncology</em>, Llovet discussed the positive results from the REACH-2 trial and how its results are shaping future combinations therapies for the treatment of patients with advanced HCC.

In an interview with <em>Targeted Oncology</em>, Chong, a fellow at the University of Pennsylvania, discussed the 4-year follow-up data for CAR T cells in patients with DLBCL and FL. She also addressed the challenges that need to be overcome in order to give more patients access to this type of therapy.

In the phase I/II TRANSCEND CLL 004 study, chimeric antigen receptor T-cell therapy lisocabtagene maraleucel led to undetectable minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia.

With 5 tyrosine kinase inhibitors approved for the treatment of patients with hepatocellular carcinoma, the next step for research in this treatment paradigm is focused on identifying the appropriate sequence of these agents.

Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with&nbsp;<em>Targeted Oncology</em>.

The FDA has granted an orphan drug designation to MB-102, a CD123-directed CAR T-cell therapy, for the treatment of patients with acute myeloid leukemia.

The FDA has granted a breakthrough therapy designation for the combination of pembrolizumab and lenvatinib for the treatment of patients with newly diagnosed, advanced, unresectable hepatocellular carcinoma that is not amenable to locoregional treatment.

In an interview with&nbsp;Targeted Oncology, Richard S. Finn, MD, discussed the findings from the KEYNOTE-240 trial. He says that although these results were not statistically significant, they are still clinically meaningful.

Novel agent namodenoson demonstrated tolerability in a favorable safety profile in patients with advanced hepatocellular carcinoma and severe liver dysfunction, according to the results of a randomized phase II trial.

Treatment with 3D conformal radiotherapy prior to hepatectomy significantly improved post-operative outcomes compared with surgery alone in patients with resectable hepatocellular carcinoma and portal vein tumor thrombus, according to the results of randomized study published in the&nbsp;<em>Journal of Clinical Oncology</em>.<br /> &nbsp;

Martin E. Gutierrez, MD, director, Drug Discovery/Phase I Unit, and co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the early findings for H3B-6527, an FGFR4 inhibitor, as a treatment of patients with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma